Changes to naming conventions and interchangeability labels are just some of the regulatory barriers standing in the way of biosimilar uptake, according to Kaiser Permanente researchers.
Timothy Chiu, PharmD, is the pharmacist evidence analyst and strategist in oncology
and Catherine Pham, PharmD, MPH, is a pharmacoeconomics and policy fellow at Kaiser Permanente.
Transcript:
What are some regulatory barriers to biosimilar uptake in the United States?
Chiu: So, there are a lot of factors that can contribute to uptake of biosimilars. From the regulatory standpoint, I think that there still are some narratives out there that may lead to some misunderstanding or misinterpretation of the scientific rigor that goes into biosimilar approvals and review.
Narratives are very important. I've seen statements out there that may suggest that the confidence in biosimilar data, even though a conclusion may be that they're noninferior or no clinically meaningful difference to a reference product, or that because a number was a certain way, or the study design was conducted in a certain population, that we wouldn't be able to have the confidence in the biosimilar that we have in the reference product.
I think that's where the complication and the additional rigor to the regulatory review is an opportunity to educate the field and continue to reinforce that we should have confidence in the regulatory review, particularly from the European experience. They've had their report out for a couple years now. Their review and workflow has led to outcomes that have been very exciting and allowed for affordability and access. Those are some of the considerations.
Pham: I think that there have been some regulatory things that have changed over time. With the naming convention, that has changed from when biosimilars were first introduced. I think that causes some confusion for providers and patients alike.
Also, the introduction of the interchangeability designation, I think, has also led to some questions. Does that mean because it's not interchangeable? Does that mean that's not something that we should be using in place of the reference drug? So, I think the more you add nuances, the more opportunity people have questions and concerns about these products.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Refining Precision Prevention for Benign Breast Disease
December 7th 2023Many questions remain surrounding accurately classifying the risk of developing invasive breast cancer associated with the benign breast disease diagnoses of nonproliferative lesions and proliferative changes without atypia.
Read More
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More